Gilead Sciences announced a definitive asset purchase agreement to acquire Repare Therapeutics’ polymerase theta (Polθ) ATPase inhibitor RP‑3467. The transaction is valued at up to $30 million, comprising a $25 million upfront payment and a $5 million milestone payment tied to regulatory and commercial milestones.
RP‑3467 is a late‑stage oncology candidate that blocks the DNA‑repair enzyme Polθ, a target linked to resistance against DNA‑damaging therapies. By adding RP‑3467 to its portfolio, Gilead expands its precision‑oncology platform beyond its existing assets such as the antibody‑drug conjugate Trodelvy and the hepatitis‑C drug Livdelzi, positioning the company to develop combination regimens that may improve outcomes in solid tumors.
The acquisition aligns with Gilead’s strategy to diversify beyond its core HIV business while leveraging its strong cash position. As of September 30, 2025, Gilead held $9.4 billion in cash, cash equivalents, and marketable debt securities, and $10 billion in the same category at the end of Q4 2024. The modest $30 million price tag reflects the early‑stage nature of RP‑3467 and the company’s intent to use the deal as a strategic foothold in oncology rather than a blockbuster acquisition.
Repare Therapeutics is also in the process of being acquired by XenoTherapeutics. The sale of RP‑3467 to Gilead is expected to improve the terms for Repare shareholders in the Xeno deal, potentially raising the per‑share payment to roughly $2.20. Repare CEO Steve Forte said the transaction “provides a strong liquidity event for the company and its investors while positioning RP‑3467 for further development.”
Gilead’s oncology strategy focuses on building a diversified pipeline that includes antibody‑drug conjugates, small‑molecule inhibitors, and cell‑based therapies. RP‑3467’s novel mechanism of action complements this strategy by targeting a DNA‑repair pathway that is often up‑regulated in tumors with homologous recombination deficiencies. The acquisition therefore strengthens Gilead’s ability to offer combination therapies that may overcome resistance to existing treatments.
The deal is a material event that signals Gilead’s continued commitment to expanding its oncology footprint and demonstrates its willingness to invest in early‑stage assets that could become part of its future revenue streams.
revised_sentiment_rating
importance
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.